Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMcCleary, Nadine Jackson
dc.contributor.authorHarmsen, William
dc.contributor.authorHaakenstad, Ellana
dc.contributor.authorCleary, J. M.
dc.contributor.authorMeyerhardt, Jeffrey
dc.contributor.authorZalcberg, John
dc.contributor.authorTabernero Caturla, Josep
dc.date.accessioned2022-09-07T11:55:40Z
dc.date.available2022-09-07T11:55:40Z
dc.date.issued2022-04
dc.identifier.citationMcCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, et al. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectr. 2022 Apr;6(2):pkac014.
dc.identifier.issn2515-5091
dc.identifier.urihttp://hdl.handle.net/11351/8053
dc.descriptionMetastatic Colorectal Cancer; Outcomes
dc.description.abstractBackground We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials. Methods Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided. Results Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively). Conclusions Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesJNCI Cancer Spectrum;6(2)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/therapy
dc.subject.meshTreatment Outcome
dc.titleMetastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/jncics/pkac014
dc.subject.decsneoplasias colorrectales
dc.subject.decs/terapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1093/jncics/pkac014
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[McCleary NJ, Haakenstad E, Cleary JM, Meyerhardt JA] Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA. [Harmsen WS] Department of Health Science Research, Mayo Clinic, Rochester, MN, USA. [Zalcberg J] Monash University, Melbourne, Australia. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institute of Oncology Barcelona-Quiron, UVic-UCC, Barcelona, Spain
dc.identifier.pmid35603849
dc.identifier.wos000771125700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record